Abstract\nBACKGROUND: Additon of docetaxel to androgen deprivation therapy(ADT) as first –line treatment in high volume metastatic hormone-sensitive (hormone naïve) prostate cancer(mHSPC). The Sun sets on ADT alone in mHSPC after the results of CHAARTED trial and STAMPEDE trial, that showed significant improvement in overall survival after addition of docetaxel to ADT in comparison to ADT alone. \n\nMETHODS: From January 2012 to January 2014, 46 patients with newly diagnosed metastatic hormone sensitive prostate cancer with confirmed measurable high-volume metastatic disease, were enrolled Eligible. Patients received androgen-deprivation therapy (with a long-acting GnRH agonist ([Goserelin acetate, 3.6 mg subcutaneously monthly] and an androgen antagonist [Flutamide®, 750 mg daily]) plus docetaxel (at a dose of 75mg/m2 given as an intravenous infusion every 3 weeks × 6 cycles).\n \nRESULTS: The median follow up period was 49 months ± SE 4.905\nMedian progression free survival (PFS) was 28 months ± SE 1.787 .The 2-year PFS rate was 58.6% .Median overall survival (OS) was 49 months ± SE 4.905. The 2-year OS rate was 85.9%.\n \n CONCLUSIONS: Docetaxel in addition to ADT should be considered SOC for men with newly diagnosed mHSPC.\n\nKEYWORDS: Androgen deprivation therapy, Metastatic hormone-sensitive prostate cancer, Metastatic castration-resistant prostate cancer, Taxanes, Docetaxel.